'GC Cell Launches Liver Cancer Awareness on February 2, Liver Cancer Day, with Biannual Dual Testing'

GC Cell (GCsel) announced on February 5th that it held an in-house event on February 2nd to commemorate 'Liver Cancer Day.'

On the 2nd, at GC Cell's in-house event for 'Liver Cancer Day,' Professor Lee Hye-won from Severance Hospital is giving a presentation. [Photo by GC Cell]

The event, held simultaneously at the GC Cell R&D Center and online, was attended by about 300 GC Cell executives and employees, including CEO James Park. The speakers included Professor Hye-won Lee from Severance Hospital's Department of Gastroenterology and Mira Seo, Unit Head of GC Cell’s Excellent Good Manufacturing Practice (GMP) Manufacturing Division, who shared the necessity of early diagnosis of liver cancer and the clinical effects of immune cell therapy.

Every year, February 2nd is designated as Liver Cancer Day by the Korean Liver Cancer Association in 2017. The day was established to raise public awareness of the risks of liver cancer and the importance of early screening, emphasizing the importance of regularly undergoing 'two' liver ultrasounds and 'two' serum alpha-fetoprotein tests annually.

According to the national cancer registry statistics released last year, the number of new cancer cases in South Korea in 2021 was 277,523. Among them, new liver cancer patients numbered 15,131 (5.5%), ranking seventh after thyroid, colorectal, lung cancers, and others. The recent 5-year relative survival rate for liver cancer (2017?2021) is 39.3%, significantly lower than the overall cancer relative survival rate of 72.1%. While early diagnosis of liver cancer increases the 5-year survival rate to about 70% or higher, late diagnosis results in a survival rate below approximately 16%, highlighting the importance of early screening and appropriate treatment.

During the event, lectures were given on the causes, diagnosis, and treatment methods of liver cancer. Detailed information and the clinical significance of GC Cell’s immune cell therapy, 'ImmunCell LC Injection,' were introduced. In a Phase 3 clinical trial targeting early hepatocellular carcinoma patients, ImmunCell LC Injection demonstrated a 37% reduction in recurrence risk and a 79% reduction in mortality compared to the control group. Based on these results, it was approved as a post-surgical treatment for liver cancer and has recently accumulated data from 10,000 treated patients.

Professor Hye-won Lee stated, “Commemorating Liver Cancer Day, we emphasized the importance of early treatment for liver cancer, which has a high recurrence rate, and therapies to prevent recurrence after surgery. It was a meaningful time to deliver accurate information about liver cancer and engage in communication.”

This content was produced with the assistance of AI translation services.